Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer

NEXT STORY
Medigene, IRICoR and Université de Montréal Sign Collaboration and Exclusive Licensing Option on Novel Cancer Antigens
PREV STORY
Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Relypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016

REDWOOD CITY, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma ...

author_avatar
NASDAQ Market News

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2018 Financial Results

Conference Call Scheduled for July 19, 2018 at 11:00 am EASTERNDUBLIN, Ireland, July 12, ...

author_avatar
NASDAQ Market News

Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

author_avatar
NASDAQ Market News